Aratana Therapeutics, a US-based biopharmaceutical company which develops pet medicines based on therapies for humans, raised $35m in an initial public offering (IPO) on Nasdaq, offering 5.8 million shares at $6, having originally filed to offer 4.3 million shares at a price range of $11 to $13 per share. Aratana has a market capitalisation of $119m.
Aratana’s shareholders include MPM Ventures, Avalon Ventures, Cultivian Ventures and RaQualia Pharma, which provides clinical and pre-clinical candidates for human patients.
Stifel and Lazard acted as lead managers on the IPO.
Previously in February 2013, Aratana raised $12m in its series C round; in December 2011, it raised $15m in its B round and $20m in an A round at the start of that year. Aratana Therapeutics was founded in 2010.